Abivax reports 2021 financial results and operations up

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022

Related Keywords

Japan , Germany , Paris , France General , France , United Kingdom , Belarus , Italy , San Diego , California , United States , Houston , Texas , Russia , Spain , Ukraine , Ukrainian , Pbruce Sands , William Sandborn , Kepler Cheuvreux , Enregistrement Universel , Hartmut Ehrlich , Scripps Md Anderson Cancer Center , Md Anderson Cancer Center , American College Of Rheumatology , Company Board Of Directors On , Research Tax Credit , European Medicines Agency , Bristol Myers Squibb , Euronext , Euronext Paris , Mayo Score , Cancer Center , Annual Shareholders , French Autorit , Des March , Modified Mayo Score , American College , Abivax Stock Exchange , News , Information , Press Release , Abivax , Biotechnology , Company , Developing , Novel , Therapies , Hat , Modulate , The , Immune , System , O , Treat , Hronic , Inflammatory , Viral , End , Oday , Nnounces Abvx Fr0012333284 ,